Alembic Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,603 Cr +36.3% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
AP

Alembic Pharmaceuticals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,150Cr
+25.7% YoY
+16.3% QoQ
Net profit
₹172Cr
+11.7% YoY
−14.9% QoQ
Margin
15%
−1 pp YoY
+3 pp QoQ

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹844
Market cap₹16.6K Cr
P/E22.3

The short version

US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).

From Alembic Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4).
  • US branded specialty business projected to scale up over next few quarters and start contributing positively to profit from FY28 onwards (Pages 6,14).
  • Around 15 new product launches planned in the US in next 9 months, with a similar number expected next year, supporting sustained US growth (Page 13).
  • ROW (Rest of World) markets expected to achieve around 15% growth in INR terms in FY27, with potential to surpass this depending on market conditions (Page 14).

2 more points from Alembic Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
  • Preventive debottlenecking and maintenance upgrades were done in facilities (e.g., Ophthaline) to expand capacity without incremental capex.
  • Strategic investments ongoing in R&D, manufacturing capabilities, and US branded business platform.
  • Investments in US branded platform focus on building commercial capabilities and scaling specialty franchises; primarily marketing and field force costs with no manufacturing asset investments.
  • Working on peptide development, regulatory filings, and portfolio development initiatives as part of R&D capital.

2 more points from Alembic Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Alembic Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Alembic Pharmaceuticals Ltd Q1 FY27 results — key figures

Alembic Pharmaceuticals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue2,1501,711+25.7%1,848+16.3%
Operating profit (EBITDA)332281+18.1%228+45.6%
Operating margin15%16%-1 pp12%+3 pp
Profit before tax222190+16.8%119+86.6%
Net profit (PAT)172154+11.7%202-14.9%
EPS (₹)8.807.85+12.1%10.31-14.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹334 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alembic Pharmaceuticals Ltd Q1 FY27 results?

US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).

What is Alembic Pharmaceuticals Ltd share price analysis?

Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.3 with a market cap of ₹16,624 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alembic Pharmaceuticals Ltd planning capital expenditure?

Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.

Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.